{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:51Z","timestamp":1786976091440,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd011612.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000}}],"reference-count":236,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011612.pub3","type":"journal-article","created":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T22:02:04Z","timestamp":1631397724000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder"],"prefix":"10.1002","volume":"2021","author":[{"given":"Rebecca L","family":"Dean","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Hurducas","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Hawton","sequence":"additional","affiliation":[{"name":"Centre for Suicide Research, Department of Psychiatry; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Spyridi","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Sciences, Faculty of Health Sciences; Cyprus University of Technology; Lemesos Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Cowen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hollingsworth","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahnee","family":"Marquardt","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Barnes","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Smith","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert","family":"McShane","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"},{"name":"Department of Psychiatry; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick H","family":"Turner","sequence":"additional","affiliation":[{"name":"Portland Veterans Affairs Medical Center; P3MHDC; Portland USA"},{"name":"Department of Psychiatry; Oregon Health & Science University; Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust; Oxford UK"},{"name":"Department of Psychiatry; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,12]]},"reference":[{"key":"10.1002\/14651858.CD011612.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajp.2015.04.002","article-title":"Memantine in the prevention or alleviation of electroconvulsive therapy induces cognitive disorders: a placebo controlled trial","volume":"15","author":"Abbasinazari","year":"2015","journal-title":"Asian Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jcpt.12469","article-title":"Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: ramdomized, double-blind, placebo-controlled study","volume":"42","author":"Amidfar","year":"2016","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S2215-0366(17)30077-9","article-title":"Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"Arabzadeh","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.13m08454","article-title":"The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial","volume":"75","author":"Berk","year":"2014","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"620630","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind randomised placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/ANA.0000000000000511","article-title":"Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: a randomised clinical trial","volume":"30","author":"Carspecken","year":"2018","journal-title":"Journal of Neurosurgical Anesthesiology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/YCT.0000000000000636","article-title":"Effects of low-dose ketamine on the antidepressant efficacy and suicidal ideations in patients undergoing electroconvulsive therapy","volume":"36","author":"Chen","year":"2020","journal-title":"Journal of ECT"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/YCT.0000000000000365","article-title":"Effect of Low dose of ketamine on learning memory function in patients undergoing electroconvulsive therapy-a randomized, double-blind, controlled clinical study","volume":"33","author":"Chen","year":"2017","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jad.2017.09.008","article-title":"Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment resistant depression: a randomized control study","volume":"225","author":"Chen","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","article-title":"Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double blind, non-inferiority study","volume":"264","author":"Correia-Melo","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2470547018796102","article-title":"Ketamine, but not the NMDAR antagonist lanicemine, increases prefrontal global connectivity in depressed patients","volume":"2","author":"Abdallah","year":"2018","journal-title":"Chronic Stress"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.euroneuro.2016.03.006","article-title":"Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate","volume":"26","author":"Downey","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0016|cit16","unstructured":"Fava M Freeman MP Flynn M Judge H Hoeppner BB Cusin C Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) Molecular Psychiatry 10.1038\/s41380-018-0256-5"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenousketamine as adjunctive therapy in treatment-resistant depression(TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Molecular Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressantin treatment-resistant depression: results of a randomized, double-blind, active-controlled study(TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0019|cit19","unstructured":"Fedgchin M Trivedi M Daly EJ Melkote R Lane R Lim P Randomized, double-blind study of fixed-dose intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression Poster presentation at the 9th Biennial Conference of the International Society for Affective Disorders and the Houston Mood Disorders Conference"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1192\/bjp.bp.116.189134","article-title":"Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial","volume":"210","author":"Fernie","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0021|cit21","first-page":"e1","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (Aspire I)","volume":"81","author":"Fu","year":"2020","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0269881118760660","article-title":"Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial","volume":"32","author":"G\u00e1lvez","year":"2018","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.psychres.2013.12.008","article-title":"Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder","volume":"215","author":"Ghasemi","year":"2013","journal-title":"Psychiatry Research"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2006.03.004","article-title":"Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder","volume":"93","author":"Heresco-Levy","year":"2006","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","article-title":"A Randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression","volume":"16","author":"Heresco-Levy","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1017\/S0033291715002159","article-title":"Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a ransomized, placebo-controlled 4-week study","volume":"46","author":"Hu","year":"2016","journal-title":"Psychological Medicine"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","article-title":"Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression","volume":"74","author":"Huang","year":"2013","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs Add-on riluzole: Results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jad.2018.09.037","article-title":"Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial","volume":"243","author":"Ionescu","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2020","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/YCT.0000000000000158","article-title":"efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression","volume":"30","author":"Jagtiani","journal-title":"Journal of ECT"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/psychiatry.IndianJPsychiatry_386_18","article-title":"Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression","volume":"61","author":"Jagtiani","year":"2019","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/YCT.0b013e318283b7e9","article-title":"Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study","volume":"29","author":"Jarventausta","year":"2013","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5152\/TJAR.2015.92668","article-title":"Effect of ketamine, thiopental and ketamine-thiopental combination during electroconvulsive therapy for depression","volume":"43","author":"Kuscu","year":"2015","journal-title":"Turkish Journal of Anaesthesiology and Reanimation"},{"issue":"12","key":"10.1002\/14651858.CD011612.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/hbm.23085","article-title":"The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study","volume":"37","author":"Li","journal-title":"Human Brain Mapping"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jad.2012.04.032","article-title":"Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial","volume":"142","author":"Loo","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4088\/JCP.v68n0414","article-title":"Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study","volume":"68","author":"Michelson","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/npp.2014.298","article-title":"Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial","volume":"40","author":"Murrough","year":"2015","journal-title":"Neuropsychopharmacology."},{"key":"10.1002\/14651858.CD011612.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations","year":"2012","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: An exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations","year":"2012","journal-title":"Journal of psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Ochs-Ross R Daly EJ Lane R Zhang Y Lim P Foster K Efficacy and safety of intranasal esketamine plus an oral antidepressant in elderly patients with treatment-resistant depression Poster presentation at the 2018 Annual Meeting of the American Psychiatric Association","DOI":"10.1016\/j.biopsych.2018.02.1005"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression - TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am J of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0048|cit48","first-page":"525","article-title":"Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study","volume":"19","author":"Omranifard","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/01.pra.0000462606.17725.93","article-title":"Randomized proof of concept trial of GLYX-13, an N-Methyl-D-Aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent","volume":"21","author":"Preskorn","journal-title":"Journal of Psychiatric Practice"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"675684","DOI":"10.1001\/jamapsychiatry.2016.0838","article-title":"Efficacy and safety of basimglurant as adjunctive therapy for major depression","volume":"73","author":"Quiroz","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/WNF.0000000000000185","article-title":"Citicoline combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial","volume":"40","author":"Roohi-Azizi","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jpsychires.2016.01.003","article-title":"Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial","volume":"75","author":"Salardini","year":"2016","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"486","DOI":"10.4103\/0971-9784.166444","article-title":"Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial","volume":"18","author":"Salehi","year":"2015","journal-title":"Annals of Cardiac Anaesthesia"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Molecular Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"844853","DOI":"10.1038\/npp.2016.224","article-title":"Adjunctive lanicemine (AZD6765) in oatients with major depressive disorder and history of inadequate response to antidepressants: randomized, placebo-controlled study","volume":"42","author":"Sanacora","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e1578","DOI":"10.17795\/ijpbs-1578","article-title":"Antidepressant effect of combined ketamine and electroconvulsive therapy on patients with major depressive disorder: a randomized trial","volume":"9","author":"Shams Alizadeh","year":"2015","journal-title":"Iranian Journal of Psychiatry and Behavioural Sciences"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Translational Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD011612.pub3-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A Double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4088\/JCP.12m08252","article-title":"Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: A randomized, double-blind, placebo-controlled trial","volume":"74","author":"Smith","year":"2013","journal-title":"Journal of Clinical Psychiatry Diseases of the Nervous System"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0064|cit64","first-page":"287","article-title":"Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression","volume":"34","author":"Sos","year":"2013","journal-title":"Neuro Endocrinology Letters"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jad.2019.08.022","article-title":"Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: a double-blind, placebo-controlled, randomized, longitudinal resting fMRI study","volume":"259","author":"Chen","year":"2019","journal-title":"Journal of Affected Disorders"},{"issue":"13","key":"10.1002\/14651858.CD011612.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Gueorguieva","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bpsc.2019.07.002","article-title":"Ketamine Enhances Visual Sensory Evoked Potential Long-term Potentiation in Patients With Major Depressive Disorder","volume":"5","author":"Sumner","year":"2020","journal-title":"Biological Psychiatry: Cognitive Neuroscience and Neuroimaging"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41398-020-0844-4","article-title":"A randomized placebo-controlled PET study of ketamine's effect on serotonin1B receptor binding in patients with SSRI-resistant depression","volume":"10","author":"Tiger","year":"2020","journal-title":"Translational Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"18m12470","DOI":"10.4088\/JCP.18m12470","article-title":"Randomised, double-blind, placebo-controlled trial of the mglu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht","year":"2020","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/YCT.0b013e3182a4b4c6","article-title":"Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study","volume":"30","author":"Yoosefi","year":"2014","journal-title":"Journal of ECT"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1176\/appi.ajp.163.1.153","article-title":"A double-blind, placebo-controlled study of memantine in the treatment of major depression","volume":"163","author":"Zarate","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"342","DOI":"10.15690\/vramn1158","article-title":"Placebo-controlled study of xenon effect on the emotions and frequency of the EEG alpha-oscillations [Russian]","volume":"74","author":"Aftanas","year":"2019","journal-title":"Vestnik Rossiiskoi Akademii Meditsinskikh Nauk"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cap.2004.14.593","article-title":"The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: A retrospective chart review","volume":"14","author":"Barzman","year":"2005","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S1461145799001686","article-title":"Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences","volume":"3","author":"Bondolfi","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.7205\/MILMED-D-15-00431","article-title":"A double-blinded, randomized, placebo-controlled sub-dissociative dose ketamine pilot study in the treatment of acute depression and suicidality in a military emergency department setting","volume":"181","author":"Burger","year":"2016","journal-title":"Military Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852920001194","article-title":"Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression","volume":"26","author":"Chen","year":"2020","journal-title":"CNS Spectrums"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s00540-014-1899-2","article-title":"Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy","volume":"29","author":"Erdil","year":"2015","journal-title":"Journal of Anasthesia"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2014.09.005","article-title":"Fast BDNF serum level increase and diurnal BDNF oscillations are associated with therapeutic response after partial sleep deprivation","volume":"59","author":"Giese","year":"2014","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4088\/JCP.v66n0519f","article-title":"Development of subtle psychotic symptoms with memantine: A case report 4 [letter]","volume":"66","author":"Huey","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1089\/jpm.2010.9808","article-title":"Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care","volume":"13","author":"Irwin","year":"2010","journal-title":"Journal of Palliative Medicine"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/15622970701420481","article-title":"Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression","volume":"10","author":"Liebrenz","year":"2009","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1016\/j.euroneuro.2019.09.585","article-title":"P. 601 AXS-05 (dextromethorphan\/bupropion), a novel, oral, investigational agent for major depressive disorder: Results of a randomized, double-blind, active-controlled, multi-center trial (ASCEND).","volume":"29","author":"O'Gorman","year":"2019","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/acps.13216","article-title":"The effects of ketamine on typical and atypical depressive symptoms","volume":"142","author":"Park","year":"2020","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.psychres.2013.12.027","article-title":"A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy","volume":"215","author":"Rasmussen","year":"2014","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.2019.135","article-title":"Potential differences in antidepressant effects of oral ketamine liquid suspension versus compounded capsules","volume":"215","year":"2019","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2020.07.066","article-title":"Antidepressant effects of ketamine and ECT: a pilot comparison","volume":"276","author":"R","year":"2020","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","article-title":"A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression","volume":"10","author":"Shiroma","year":"2020","journal-title":"Translational Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jad.2017.11.034","article-title":"A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression","volume":"227","author":"Zhang","year":"2018","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jad.2016.05.011","article-title":"Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression","volume":"201","author":"Zhong","year":"2016","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0092|cit92","unstructured":"Comparison of the effect of electroconvulsive therapy and intravenous infusion of ketamine on control and relapse of depressive symptoms in depressive cases who are candidates of electro convulsive therapy http:\/\/www.irct.ir\/searchresult.php?id=2266&number=2"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0093|cit93","unstructured":"Effectiveness of the dual serotonin norepinephrine reuptake inhibitor venlafaxine in depressed patients http:\/\/www.isrctn.com\/ISRCTN87057460"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0094|cit94","unstructured":"A Phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female subjects fulfilling the criteria for major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT01046630"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0095|cit95","unstructured":"A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase IIb efficacy and safety study of adjunctive AZD6765 in patients with major depressive disorder (MDD) and a history of inadequate response to antidepressants study D6702C00031 http:\/\/clinicaltrials.gov\/show\/NCT01482221"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0096|cit96","unstructured":"A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of ketamine in subjects with treatment-resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01627782"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0097|cit97","unstructured":"Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=Vestibular+Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0098|cit98","unstructured":"Ketamine augmentation of ECT to improve outcomes in depression - Ketamine-ECT study https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2011-005476-41\/GB"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0099|cit99","unstructured":"Riluzole as adjuvant therapy in the treatment of moderate to severe major depression: a double - blind placebo-controlled trial http:\/\/www.irct.ir\/searchresult.php?keyword=&id=1556&number=54&prt=5237&total=10&m=1"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0100|cit100","unstructured":"Memantine augmentation of electroconvulsive therapy in patients with major depression http:\/\/clinicaltrials.gov\/show\/NCT00988663"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0101|cit101","unstructured":"A safe ketamine-based therapy for treatment resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01179009"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0102|cit102","unstructured":"Efficacy and tolerability of riluzole in treatment resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01204918"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0103|cit103","unstructured":"N-methyl-D-aspartate antagonist (ketamine) augmentation of electroconvulsive treatment for severe major depression http:\/\/clinicaltrials.gov\/show\/NCT01260649"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0104|cit104","unstructured":"A study of ketamine as an antidepressant http:\/\/clinicaltrials.gov\/show\/NCT01441505"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0105|cit105","unstructured":"Estimate the efficiency of the association of an injection of ketamine and the venlafaxine in the severe major depressive disorder for six weeks (KETADEP) http:\/\/clinicaltrials.gov\/show\/NCT01557712"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0106|cit106","unstructured":"The antidepressant action of ketamine: brain chemistry http:\/\/clinicaltrials.gov\/show\/NCT01558063"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0107|cit107","unstructured":"Combination of anticholinergic and glutamatergic effects in treatment-resistant major depressive disorder. A pilot study http:\/\/clinicaltrials.gov\/show\/NCT01613820"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0108|cit108","unstructured":"Randomized, double-blind ketamine augmentation in chronically suicidal, treatment-resistant major depression http:\/\/clinicaltrials.gov\/show\/NCT01667926"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0109|cit109","unstructured":"Phase 2, double-blind, placebo controlled, randomized withdrawal, parallel efficacy and safety study of GLYX-13 in subjects with inadequate\/partial response to antidepressants during the current episode of major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT01684163"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0110|cit110","unstructured":"Ketamine vs. midazolam: testing rapid relief of suicide risk in depression http:\/\/clinicaltrials.gov\/show\/NCT01700829"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0111|cit111","unstructured":"Riluzole augmentation pilot in depression (RAPID) trial http:\/\/clinicaltrials.gov\/show\/NCT01703039"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0112|cit112","unstructured":"Ketamine for treatment-resistant depression: a multicentric clinical trial in Mexican population http:\/\/clinicaltrials.gov\/show\/NCT01868802"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0113|cit113","unstructured":"Ketamine plus lithium as a novel pharmacotherapeutic strategy in treatment-resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01880593"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0114|cit114","unstructured":"Comparing therapeutic efficacy and cognitive side effects of electroconvulsive therapy (ECT) using ketamine versus methohexital anesthesia http:\/\/clinicaltrials.gov\/show\/NCT01881763"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0115|cit115","unstructured":"Targeting the NMDA glutamate receptor as novel antidepressant strategy: a pilot clinical trial of nuedexta in treatment-resistant major depression http:\/\/clinicaltrials.gov\/show\/NCT01882829"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0116|cit116","unstructured":"Treatment of suicidal ideation with intravenous ketamine infusion http:\/\/clinicaltrials.gov\/show\/NCT01887990"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0117|cit117","unstructured":"Treatment of geriatric depression with mild cognitive impairment: a double-blind placebo-controlled trial of namenda (memantine) augmentation of lexapro (escitalopram) in depressed patients at least 60 years of age http:\/\/clinicaltrials.gov\/show\/NCT01902004"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0118|cit118","unstructured":"Double-blind, placebo-controlled trial of ketamine therapy in treatment-resistant depression (TRD) http:\/\/clinicaltrials.gov\/show\/NCT01920555"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0119|cit119","unstructured":"A prospective randomized double blinded control trial using ketamine or propofol anesthesia for electroconvulsive therapy: improving treatment-resistant depression http:\/\/clinicaltrials.gov\/show\/NCT01935115"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0120|cit120","unstructured":"Ketamine vs. midazolam in bipolar depression http:\/\/clinicaltrials.gov\/show\/NCT01944293"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0121|cit121","unstructured":"Phase 2 optimization of the antidepressant action of ketamine in treatment-resistant depression and investigations on its mechanism of action http:\/\/clinicaltrials.gov\/show\/NCT01945047"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0122|cit122","unstructured":"An open-label and double-blind study to investigate evoked potentials as markers of ketamine-induced cortical plasticity in subjects with major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT01957410"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0123|cit123","unstructured":"Ketamine use in electroconvulsive therapy: clinical, cognitives and neurotrophic outcomes http:\/\/clinicaltrials.gov\/show\/NCT02012335"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0124|cit124","unstructured":"Double blind, non-inferiority study to evaluate the antidepressant activity of ETS6103 compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who have an unsatisfactory response to selective serotonin re-uptake Inhibitors (SSRIs) http:\/\/clinicaltrials.gov\/show\/NCT02014363"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0125|cit125","unstructured":"Effect of oral ketamine treatment on suicidal ideation and drug resistant major depression, a clinical and fMRI study http:\/\/clinicaltrials.gov\/show\/NCT02037503"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0126|cit126","unstructured":"Phase 2, randomized, double-blind, multiple-dose level, placebo controlled, single intravenous dose, parallel efficacy and safety study of NRX-1074 in subjects with major depressive disorder http:\/\/clinicaltrials.gov\/show\/NCT02067793"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0127|cit127","unstructured":"A randomized, double-blinded controlled trial of an N-methyl D-aspartate antagonist as a rapidly-acting antidepressant in depressed emergency department patients http:\/\/clinicaltrials.gov\/show\/NCT02106325"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0128|cit128","unstructured":"Nitrous oxide as treatment for major depression - a pilot study http:\/\/clinicaltrials.gov\/show\/NCT02139540"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0129|cit129","unstructured":"A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterium modified dextromethorphan hydrobromide\/quinidine sulfate) as an adjunctive therapy in patients with Major depressive disorder with an inadequate response to antidepressant treatment http:\/\/clinicaltrials.gov\/show\/NCT02153502"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0130|cit130","unstructured":"Effect of the addition of ketamine to sevoflurane anesthesia in electroconvulsive therapy http:\/\/clinicaltrials.gov\/show\/NCT02267980"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0131|cit131","unstructured":"Intranasal ketamine for late-life depression and suicidal ideation http:\/\/clinicaltrials.gov\/show\/NCT02295787"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0132|cit132","unstructured":"Evaluation of the effects of ketamine in the acute phase of suicidal ideation: a multicenter randomized double-blind trial http:\/\/clinicaltrials.gov\/show\/NCT02299440"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0133|cit133","unstructured":"Effect of subanesthetic dose of ketamine combined with propofol on cognitive function in depressive patients undergoing electroconvulsive therapy - a randomized control double-blind clinical trial http:\/\/clinicaltrials.gov\/show\/NCT02305394"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0134|cit134","unstructured":"Ketamine interleaved with electroconvulsive therapy for depression https:\/\/clinicaltrials.gov\/show\/NCT04082858. 2019"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0135|cit135","unstructured":"Opiate Suicide Study in Patients With Major Depression (AFSP)"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0136|cit136","unstructured":"Intramuscular ketamine versus aripiprazole and escitalopram in the treatment of resistant depression https:\/\/clinicaltrials.gov\/show\/NCT04234776. 2019"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0137|cit137","unstructured":"The Effect of S-ketamine for patients undergoing electroconvulsive therapy (ECT https:\/\/clinicaltrials.gov\/show\/NCT04399070. 2020"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0138|cit138","unstructured":"ECT and Memantine http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=3753"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12888-020-02672-3","article-title":"A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol","volume":"20","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0140|cit140","doi-asserted-by":"crossref","unstructured":"Abdallah C Gueorguieva R Goktas S Purohit P Ranganathan M Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, triples the antidepressant response rate of ketamine at 2 weeks following treatment: a double-blind, placebo-controlled, cross-over, randomized clinical trial bioRxiv 2018 p.500959","DOI":"10.1101\/500959"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ebmental-2018-300074","article-title":"Reasoning under uncertainty","volume":"22","author":"Aitken","year":"2019","journal-title":"Evidence-Based Mental Health"},{"issue":"7066","key":"10.1002\/14651858.CD011612.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0143|cit143","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0144|cit144","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0145|cit145","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0146|cit146","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders. 4th edition, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0147|cit147","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007954","article-title":"Antidepressants versus placebo for depression in primary care","author":"Arroll","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD011612.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub3-BIB0150|cit150","first-page":"1428-34","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004850-199510030-00008","article-title":"Benzodiazepines for depression? A review of the literature","volume":"10","author":"Birkenhager","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"issue":"33","key":"10.1002\/14651858.CD011612.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1-56","DOI":"10.3310\/hta5330","article-title":"Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives","volume":"5","author":"Brookes","year":"2001","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/0706743719828965","article-title":"Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews.","volume":"64","author":"Brown","year":"2019","journal-title":"Canadian Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/2045125313507739","article-title":"Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy","volume":"4","author":"Caddy","year":"2014","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"9665","key":"10.1002\/14651858.CD011612.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"746-58","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006117.pub4","article-title":"Sertraline versus other antidepressive agents for depression","author":"Cipriani","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD011612.pub3-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006533.pub2","article-title":"Duloxetine versus other anti-depressive agents for depression","author":"Cipriani","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ebmental-2019-300080","article-title":"Providing the most appropriate care to our individual patients","volume":"22","author":"Cipriani","year":"2019","journal-title":"Evidence-Based Mental Health"},{"issue":"10228","key":"10.1002\/14651858.CD011612.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(19)33177-0","article-title":"Generating comparative evidence on new drugs and devices after approval","volume":"395","author":"Cipriani","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1192\/bjp.113.504.1237","article-title":"The biochemistry of affective disorders","volume":"113","author":"Coppen","year":"1967","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"545553","DOI":"10.1001\/archpsyc.58.6.545","article-title":"Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder.","volume":"58","author":"Cotter","year":"2001","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0164|cit164","unstructured":"Dean RL Marquardt T Hurducas C Spyridi S Barnes A Smith R Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0165|cit165","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2021"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0166|cit166","first-page":"367","volume-title":"Essentials of Global Mental Health","author":"De Leo","year":"2014"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","article-title":"Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic","volume":"28","author":"Diamond","year":"2014","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00019053-200725010-00003","article-title":"Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment","volume":"25","author":"Donohue","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0169|cit169","first-page":"259","volume-title":"Handbook of Assessment and Treatment Planning for Psychological Disorders","author":"Dozois D","year":"2004"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/ebmental-2019-300103","article-title":"Statistics in pills: meta-analysis of rare events","volume":"22","author":"Efthimiou","year":"2019","journal-title":"Evidence-Based Mental Health"},{"issue":"7109","key":"10.1002\/14651858.CD011612.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"629-34","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"140-9","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving crossover trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"57-63","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"72-6","DOI":"10.1093\/ije\/31.1.72","article-title":"An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"49-52","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analysis","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"7-10","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"468-70","DOI":"10.1001\/jama.297.5.468-b","article-title":"Association between unreported outcomes and effect size estimates in Cochrane meta-analyses","volume":"297","author":"Furukawa","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"531-4","DOI":"10.1097\/JCP.0b013e31814f30b1","article-title":"Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression","volume":"27","author":"Furukawa","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpsychires.2018.08.015","article-title":"Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis","volume":"105","author":"odfrey","year":"2018","journal-title":"Journal of Psychiatric Research."},{"issue":"10","key":"10.1002\/14651858.CD011612.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1017\/S0033291717003373","article-title":"Brain glutamate in medication-free depressed patients: a proton MRS study at 7 Tesla. Psychological medicine","volume":"48","year":"2018","journal-title":"Psychological medicine"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0269881119844199","article-title":"Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety","volume":"33","author":"Goh","year":"2019","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0182|cit182","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software] Available from gradepro.org. 2020"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0183|cit183","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"7132","key":"10.1002\/14651858.CD011612.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"690-3","DOI":"10.1136\/bmj.316.7132.690","article-title":"Interpreting treatment effects in randomised trials","volume":"316","author":"Guyatt","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.2051-5545.2010.tb00298.x","article-title":"Pathophysiology of depression: do we have any solid evidence of interest to clinicians?","volume":"9","author":"Hasler","year":"2010","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(09)60372-X","article-title":"Suicide","volume":"373","author":"Hawton","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0188|cit188","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0189|cit189","unstructured":"Higgins JP 7.7.3.8 Combining groups Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 edition Cochrane Collaboration"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0190|cit190","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Available from www.training.cochrane.org\/handbook. 2020 Version 6.1","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0191|cit191","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61 Suppl 6","author":"Hirschfeld","year":"2000","journal-title":"Jourmal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ebmental-2019-300090","article-title":"Barriers and incentives to recruitment in mental health clinical trials","volume":"22","author":"Jones","year":"2019","journal-title":"Evidence-Based Mental Health"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1192\/bjp.bp.112.120196","article-title":"Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials","volume":"203","author":"Koesters","year":"2013","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD011612.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","article-title":"Prevalence of depression in the community from 30 countries between 1994 and 2014","volume":"8","author":"Lim","year":"2018","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0196|cit196","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004185.pub3","article-title":"Fluoxetine versus other types of pharmacotherapy for depression","author":"Magni","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/ebmental-2019-300101","article-title":"Getting irritable about irritability?","volume":"22","author":"Malhi","year":"2019","journal-title":"Evidence-Based Mental Health"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/eb-2014-101900","article-title":"Addressing missing outcome data in meta-analysis","volume":"17","author":"Mavridis","year":"2014","journal-title":"Evidence Based Mental Health"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub3-BIB0200|cit200","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011611.pub2","article-title":"Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults","author":"McCloud","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11126-020-09830-6","article-title":"rffectiveness and safety of ketamine for unipolar depression: a systematic Review","volume":"91","author":"Memon","year":"2020","journal-title":"Psychiatric Quarterly"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"382-9","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","article-title":"Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies.","volume":"24","author":"Moriguchi","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"255-60","DOI":"10.1016\/S0165-0327(02)00120-9","article-title":"Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS)","volume":"77","author":"Muller","year":"2003","journal-title":"Journal of Affective Disorders"},{"issue":"10228","key":"10.1002\/14651858.CD011612.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(19)33178-2","article-title":"Generating comparative evidence on new drugs and devices before approval","volume":"395","author":"Naci","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jad.2013.11.014","article-title":"A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action","volume":"156","author":"Naughton","year":"2014","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0209|cit209","unstructured":"National Institute for Health and Clinical Excellence Depression in adults: The treatment and management of depression in adults (CG90) http:\/\/publications.nice.org.uk\/depression-in-adults-cg90 2009"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0165-0327(84)90018-1","article-title":"Plasma GABA levels in psychiatric illness","volume":"6","author":"Petty","year":"1984","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders","volume":"162","author":"Rapaport","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0213|cit213","unstructured":"The Cochrane Collaboration Review Manager 2020"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.mp.4001949","article-title":"Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies","volume":"12","author":"Ruhe","year":"2007","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0215|cit215","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations.","author":"Sch\u00fcnemann","year":"2013"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1017\/S1092852916000523","article-title":"Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials","volume":"21","author":"Solmi","year":"2016","journal-title":"CNS Spectrums"},{"issue":"6","key":"10.1002\/14651858.CD011612.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"773-82","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Archives General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD011612.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1119-29","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011612.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1051-63","DOI":"10.1017\/S0033291797005205","article-title":"Symptom profiles of depression among general medical service users compared with specialty mental health service users","volume":"27","author":"Suh","year":"1997","journal-title":"Psychological Medicine"},{"issue":"12","key":"10.1002\/14651858.CD011612.pub3-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Research"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4088\/JCP.v69n0908","article-title":"Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis","volume":"69","author":"Watanabe","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD011612.pub3-BIB0223|cit223","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006528.pub2","article-title":"Mirtazapine versus other antidepressive agents for depression","author":"Watanabe","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0224|cit224","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders","author":"World Health Organization (WHO)","year":"1992"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0225|cit225","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organization","year":"2008"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0226|cit226","volume-title":"The global burden of disease: 2004 update","author":"World Health Organization (WHO)","year":"2008"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0227|cit227","unstructured":"World Health Organization (WHO) Sixty-fifth World Health Assembly: daily notes on proceedings Geneva World Health Organization 2012"},{"issue":"2","key":"10.1002\/14651858.CD011612.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems.","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discovery Today"},{"issue":"12","key":"10.1002\/14651858.CD011612.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD011612.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","article-title":"Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder.","volume":"76","author":"Yoon","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.psychres.2019.07.006","article-title":"Brexanolone for postpartum depression: a meta-analysis of randomized controlled studies.","volume":"279","author":"Zheng","year":"2019","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD011612.pub3-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jad.2020.01.002","article-title":"Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies","volume":"265","author":"Zheng","year":"2020","journal-title":"Journal of Affective Disorders"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2215-0366(20)30137-1","article-title":"Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis","volume":"7","author":"Zhou","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD011612.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.euroneuro.2013.08.004","article-title":"A proposal for an updated neuropsychopharmacological nomenclature","volume":"24","author":"Zohar","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD011612.pub3-BIB0235|cit235","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011612","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","author":"Amit","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011612.pub3-BIB0236|cit236","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011612.pub2","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","author":"Caddy","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T13:52:50Z","timestamp":1667051570000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011612.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,12]]},"references-count":236,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011612.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,12]]}}}